Kura Oncology

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kura Oncology reports Q4 loss, highlights ziftomenib's AML potential

Kura Oncology's Q4 2022 performance reflects increased R&D expenses and a net loss, offset by a strong cash position supporting operations.
The company's focus on ziftomenib's positive trial data, combination studies, and patient-centric strategies positions it for future growth.
Challenges lie in managing treatment complexities, strategic resource allocation, and balancing commercial value with patient benefit.
Opportunities include upcoming milestones, exploration of combination therapies, and regulatory advancements for ziftomenib.

Kura Oncology sees positive results with ziftomenib in Q1

Kura Oncology's Q1 2023 earnings call highlighted the promising performance of ziftomenib in AML patients, supported by strong Phase 1 trial data and strategic plans for combination studies.
While facing challenges in competitive differentiation and trial execution, the company's financial stability and focus on methodical drug development underscore its long-term potential.
Opportunities lie in achieving key milestones, exploring new therapeutic applications, and leveraging a competitive edge in the menin inhibitor space for future growth and success.

Kura Oncology reports Q2 loss, sees growth in clinical trials

Kura Oncology's Q2 2023 performance reflects increased expenses but promising clinical outcomes, with strong enrollment and positive data in key trials.
Strategic strengths lie in combination studies, diversified indications, and positive trial results, positioning the company for future growth and market expansion.
Challenges include resource constraints, research prioritization, and evolving resistance issues, necessitating adaptive strategies and efficient resource management.
Opportunities for Kura Oncology include collaborations, out-licensing, and program expansions, offering avenues for operational efficiency and revenue growth.

Kura Oncology's ziftomenib shows promise in acute leukemias, financials stable

Kura Oncology's Q3 performance reflects increased expenses but maintains a strong financial position.
The company's lead drug candidate, ziftomenib, shows promise in acute leukemias, with positive response rates.
Strategic strengths include progress with menin inhibitors, successful combination approaches, and clinical collaborations.
Challenges lie in meeting enrollment timelines, addressing efficacy questions, and balancing program investments.

Kura Oncology reports promising clinical data and financial stability

Kura Oncology's Q4 2023 performance showcased positive clinical data and financial stability, positioning the company well for future growth.
While challenges in data interpretation and differentiation exist, opportunities in milestone achievements and patient-focused therapies are on the horizon.
The company's strategic focus on early therapy lines and combinability of menin inhibitors highlight its strengths in the competitive market landscape.

Kura Oncology reports promising results for ziftomenib in Q1

Kura Oncology's Q1 2024 performance reflects increased R&D expenses and promising results for ziftomenib.
Strengths lie in FDA support, encouraging safety profiles, and ongoing combo dose escalation trials.
Challenges include patient characteristics impacting therapy duration and strategic resource allocation.
Opportunities include upcoming milestones, solid tumor data disclosure, and competitor monitoring for market insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) --  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Brian Powl as Chief Commercial Officer. Mr. Powl joins Kura with more than 20 years of experience in building commercial brands in hematology and oncology, with a focus on developing and executing patient-focused strategies across sales, marketing and market access for global biotech and pharmaceutical products.

Kura Oncology Appoints Brian Powl as Chief Commercial Officer

Kura Oncology, Inc. (NASDAQ:KURA ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Pete De Spain - Senior Vice President, Investor Relations & Corporate Communications Troy Wilson - President & Chief Executive Officer Tom Doyle - Senior Vice President, Finance & Accounting Conference Call Participants Jonathan Chang - Leerink Partners Roger Song - Jefferies Peter Lawson - Barclays Li Watsek - Cantor Bijan Mekoba - Stifel Julian Harrison - BTIG Reni Benjamin - JMP Securities Operator Good afternoon, ladies and gentlemen, and welcome to the Q2 2023 Kura Oncology, Inc. Earnings Conference Call. At this time, all lines are in listen-only mode.

Kura Oncology, Inc. (KURA) Q2 2023 Earnings Call Transcript

– Enrollment in registration-directed trial of ziftomenib in NPM1-mutant AML continues to outperform projections – – First patients dosed in combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – Late-breaking clinical data for ziftomenib in NPM1-mutant AML presented at EHA – – Continued evidence of clinical activity observed in trial of tipifarnib plus alpelisib in PIK3CA-dependent HNSCC – – First-in-human study of next-generation FTI KO-2806 to begin in second half of 2023 – – $477 million in cash, equivalents and investments provide runway to mid-2026 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2023 financial results and provided a corporate update.

Kura Oncology Reports Second Quarter 2023 Financial Results

BeiGene

Exelixis

Pfizer

AstraZeneca

Merck

Novartis

One of the most aggressive and difficult-to-treat ailments, cancer is a disease that involves the uncontrolled division and growth of malignant cells. There are many types of cancer, many of which have limited cure and treatment options.

7 Best Cancer Stocks to Invest in Now

SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2023 financial results after the close of U.S. financial markets on Thursday, August 3, 2023. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology to Report Second Quarter 2023 Financial Results

Kura Oncology, Inc. has additional updated results released from the KOMET-001 study, as part of an oral late-breaker presentation shown on June 11, 2023 at the EHA; 35% achieved CR with full count recovery. The global Acute Myeloid Leukemia market is expected to reach $2.69 billion by 2028; 30% of AML patients have the NPM1 mutation and 5% to 10% have the KPT2A-rearranged mutation. KOMET-007 and KOMET-008 are two studies being launched two explore the synergistic effects of combining ziftomenib with other standard of care therapies for 1st line NPM1 and/or KMT2A-rearranged AML patients.

Kura Oncology: Targeted AML Therapy Continues To Deliver

Kura Oncology (KURA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Kura Oncology (KURA) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of common stock and pre-funded warrants. Kura is selling 5,660,871 shares of its common stock and pre-funded warrants to purchase 3,034,782 shares of its common stock in the offering. The shares of common stock are being sold at a price to the public of $11.50 per share, and the pre-funded warrants are being sold at a price to the public of $11.4999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.0001 per share. The aggregate gross proceeds to Kura from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Kura and excluding the exercise of any pre-funded warrants, are expected to be approximately $100 million. In addition, Kura has granted the underwriters a 30-day option to purchase up to an additional 1,304,347 shares of common stock. The offering is expected to close on or about June 16, 2023, subject to customary closing conditions.

Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

Shares of Kura Oncology Inc. KURA, -1.24% dropped nearly 6% in the aftermarket Tuesday after the biotech said it plans to sell $100 million worth of shares, plus an option for underwriters to buy additional shares. Kura ended the regular trading day down 1.2%.

Kura Oncology stock falls more than 5% after company announces share offering

SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $100,000,000 of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof). In connection with the offering, Kura expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the securities offered in the public offering. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be offered by Kura. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants

– 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (RP2D) – – 33% (2/6) of patients with FLT3 co-mutations and 50% (4/8) of patients with IDH co-mutations achieved a CR on ziftomenib – – Ziftomenib monotherapy drives durable remissions, with median DoR of 8.2 months – – Data suggest ziftomenib is less likely to induce menin resistance mutations – – Enrollment in Phase 2 registration-directed trial in NPM1-mutant AML continues to outperform projections – – First combination study in NPM1-mutant and KMT2A-rearranged AML on track to dose first patients this quarter – – Management to host virtual investor event at 8:00 a.m. ET on Monday, June 12 – SAN DIEGO, June 11, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced updated clinical data from KOMET-001, a Phase 1/2 clinical trial of the Company's potent and selective menin inhibitor, ziftomenib, including significant clinical activity in patients with heavily pretreated and co-mutated relapsed/refractory NPM1-mutant acute myeloid leukemia (AML).

Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress

– Late-breaking abstracts scheduled for publication on the EHA website at 16:00 CET on Thursday, June 1, 2023 – – Data from Phase 1 trial of ziftomenib to be presented at the late-breaking oral session on Sunday, June 11, 2023 – – Management to host virtual investor event at 8:00 a.m. ET on Monday, June 12, 2023 – SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that a late-breaking abstract with updated data from the Phase 1 trial of the Company's menin inhibitor, ziftomenib, has been accepted for oral presentation at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany.

Kura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) Congress

SAN DIEGO, May 23, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences:

Kura Oncology to Participate in Two Upcoming Investor Conferences

Kura Oncology, Inc. (NASDAQ:KURA ) Q1 2023 Earnings Conference Call May 10, 2023 5:00 PM ET Company Participants Pete De Spain - SVP, IR & Corporate Communications Troy Wilson - Chairman, CEO & President Thomas Doyle - SVP, Finance & Accounting Conference Call Participants Jonathan Chang - SVB Securities Roger Song - Jefferies Bradley Canino - Stifel, Nicolaus & Company Li Watsek - Cantor Fitzgerald & Co. Philip Nadeau - TD Cowen Operator Good afternoon, ladies and gentlemen, and welcome to the Q1 2023 Kura Oncology, Inc. Earnings Conference Call. [Operator Instructions].

Kura Oncology, Inc. (KURA) Q1 2023 Earnings Call Transcript

– Evolving data from Phase 1 trial of ziftomenib in NPM1-mutant AML to be presented at EHA – – Site activation and enrollment in Phase 2 registration-directed trial of ziftomenib in NPM1-mutant AML outperforming projections – – First combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML to dose first patients in the second quarter of 2023 – – Preclinical data highlighting potential use of FTIs in combination with multiple targeted therapies presented at AACR – – IND for KO-2806, a next-generation FTI, cleared by FDA – – $406 million in cash, equivalents and investments provide runway into fourth quarter of 2025 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2023 financial results and provided a corporate update.

Kura Oncology Reports First Quarter 2023 Financial Results

SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Life Sciences Conference in New York. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at 11:00 a.m. ET / 8:00 a.m. PT on May 16, 2023.

Kura Oncology to Participate in JMP Securities Life Sciences Conference

SAN DIEGO, May 03, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2023 financial results after the close of U.S. financial markets on Wednesday, May 10, 2023. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Kura Oncology to Report First Quarter 2023 Financial Results

Insteel Industries

Seabridge Gold

Investors looking for help finding the best under-the-radar stocks may have a new ally: the AI chatbot. Using the prompt “publicly traded companies that may be on the cusp of breaking out in popularity in May 2023,” the chatbot created a list of five top stocks to dig into.

3 Under-the-Radar Stocks That AI Predicts Will Soar in May

Kura Oncology: Multiple Catalysts Provide Strong Upside Potential

SAN DIEGO, April 18, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Stifel 2023 Targeted Oncology Days. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 1:00 p.m. ET / 10:00 a.m. PT on April 25, 2023.

Kura Oncology to Participate in Stifel Targeted Oncology Days

– Preclinical data support the potential for FTIs in combination with KRASG12C inhibitors and TKIs to prevent or delay emergence of adaptive resistance –

Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies

– Presentations to highlight preclinical data supporting combination of FTIs with KRASG12C inhibitors and tyrosine kinase inhibitors –

Kura Oncology Announces Acceptance of Two Abstracts for Presentation at AACR Annual Meeting

SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in the following events at upcoming investor conferences:

Kura Oncology to Participate in Upcoming Investor Conferences

Kura Oncology, Inc. (NASDAQ:KURA ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Pete De Spain - Senior Vice President of Investor Relations and Corporate Communications Troy Wilson - President and Chief Executive Officer Tom Doyle - Senior Vice President of Finance and Accounting Conference Call Participants Jonathan Chang - SVB Securities Roger Song - Jefferies Group LLC Peter Lawson - Barclays Li Watsek - Cantor Fitzgerald, L.P. Bradley Canino - Stifel Financial Corp. Eva Privitera - Cowen Inc. Reni Benjamin - JMP Securities LLC Operator Greetings, and welcome to Kura Oncology's Fourth Quarter 2022 Earnings Conference Call.

Kura Oncology, Inc. (KURA) Q4 2022 Earnings Call Transcript

– Phase 1 data for ziftomenib highlighted by 30% CR rate among 20 patients with NPM1-mutant AML treated at recommended Phase 2 dose –

News for Kura Oncology Stock (KURA)